Strategic Pathways to Global Growth
Multiple models for distributors, licensing partners, and clinical co-development. Each product has a clear entry point and proven pathway to market.
Pathway A — Consumer Products (Ready Now)
Two registered, commercially available products ready for immediate distribution.
Available Products
Target Channels
Benefits
- Products registered and ready to ship
- 36-month stability incl. ICH Zone 4B
- Premium OTC positioning
- No direct equivalent on market
- Made in Italy
- Full marketing material support
In-Pharmacy Presence
We provide distributors with complete point-of-sale materials — countertop display and floor totem — ready for pharmacy placement.
Co-Development / Licensing
For pharmaceutical partners — Phase IIb in progress, ready for licensing or co-development agreements.
Current Study
Phase IIb head-to-head vs acyclovir with PPD (Thermo Fisher Scientific). 80 patients, 7 countries, 25 sites. Started April 2026, first patient enrollment May 2026. Primary readout: 7-8 months.
Partnership Options
Post-Phase IIb readout licensing for specific territories or global rights
Joint investment in pivotal Phase III program. Shared risk/reward.
Full asset or company acquisition. IP + data room available.
ACRO-EYE & Easy-Dialysis
For partners interested in ophthalmology or medical devices — Earlier-stage programs with significant market potential.
ACRO-EYE™
Tacrolimus ophthalmic solution for KCS. No direct equivalent. Co-development or licensing opportunity.
Easy-Dialysis™
Portable hemodialysis device. Prototype complete. Investment required for CE Marking.
Request Partner Deck
Complete the form to receive our non-confidential deck and Phase IIb study summary.